Business Context and Reporting Period
This Form 8-K filing by Pluristem Therapeutics Inc. (PSTI) reports corporate governance changes effective January 5, 2021. The report was filed on January 6, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board appointments and does not contain financial performance data.
Material Changes
The Board of Directors was increased in size by two members. The following individuals were appointed to fill the resulting vacancies, effective immediately:
- Maital Shemesh-Rasmussen: Former Global Head of Marketing at Roche Diagnostics Information Solutions (2018-2020) and Vice President at JPMorgan Chase Bank (2002-2007).
- Rami Levy: Founder and President of Catalyst Group International, LLC (since 2009) and former Senior Deputy General at Israel's Ministry of Tourism (2004-2006).
Neither appointee was assigned to any Board committees at the time of appointment.
Compensation and Governance
Both new directors will receive fees identical to those of other non-executive directors, as detailed in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2020. The Company expects to enter into standard indemnification agreements with both appointees on terms consistent with existing agreements for directors and executive officers. No other arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the specific director fee amounts in the Form 10-K for the fiscal year ended June 30, 2020.
- Confirm the execution of standard indemnification agreements with Ms. Shemesh-Rasmussen and Mr. Levy.
- Monitor future filings for any committee assignments for the new directors.